This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Concert Pharmaceuticals 과거 수익 실적
과거 기준 확인 0/6
주요 정보
-45.4%
수익 성장률
-40.8%
EPS 성장률
Biotechs 산업 성장 | 17.0% |
매출 성장률 | 47.4% |
자기자본 수익률 | -94.8% |
순이익 | -395.4% |
최근 수익 업데이트 | 30 Sep 2022 |
최근 과거 실적 업데이트
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03수익 및 비용 분석
수익 및 비용 분석
Concert Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 22 | 32 | -127 | 22 | 0 |
30 Jun 22 | 33 | -125 | 22 | 0 |
31 Mar 22 | 33 | -95 | 23 | 0 |
31 Dec 21 | 33 | -80 | 23 | 0 |
30 Sep 21 | 1 | -66 | 22 | 0 |
30 Jun 21 | 2 | -59 | 21 | 0 |
31 Mar 21 | 8 | -77 | 20 | 0 |
31 Dec 20 | 8 | -75 | 19 | 0 |
30 Sep 20 | 8 | -73 | 19 | 0 |
30 Jun 20 | 6 | -71 | 19 | 0 |
31 Mar 20 | 0 | -77 | 19 | 0 |
31 Dec 19 | 1 | -78 | 20 | 0 |
30 Sep 19 | 1 | -79 | 21 | 0 |
30 Jun 19 | 1 | -79 | 22 | 0 |
31 Mar 19 | 1 | -73 | 23 | 0 |
31 Dec 18 | 11 | -56 | 23 | 0 |
30 Sep 18 | 11 | -41 | 23 | 0 |
30 Jun 18 | 11 | 104 | 21 | 0 |
31 Mar 18 | 11 | 104 | 21 | 0 |
31 Dec 17 | 0 | 95 | 21 | 0 |
30 Sep 17 | 0 | 89 | 19 | 0 |
30 Jun 17 | 0 | -50 | 18 | 0 |
31 Mar 17 | 0 | -50 | 16 | 0 |
31 Dec 16 | 0 | -51 | 14 | 0 |
30 Sep 16 | 10 | -38 | 14 | 0 |
30 Jun 16 | 12 | -35 | 14 | 0 |
31 Mar 16 | 15 | 19 | 13 | 0 |
양질의 수익: CNCE is currently unprofitable.
이익 마진 증가: CNCE is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: CNCE is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.
성장 가속화: Unable to compare CNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: CNCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.2%).
자기자본 수익률
높은 ROE: CNCE has a negative Return on Equity (-94.78%), as it is currently unprofitable.